TY - JOUR
T1 - Tumor lysis syndrome after treatment of chronic lymphocytic leukemia with cladribine
AU - Trendle, Michael C.
AU - Tefferi, Ayalew
AU - Dann, Eldad J.
AU - Rachmilewitz, Eliezer A.
AU - Rund, Deborah
PY - 1994/4/14
Y1 - 1994/4/14
N2 - To the Editor: In the November 18 issue of the Journal, Dann et al.1 reported a case of tumor lysis syndrome after treatment with 2-chlorodeoxyadenosine (cladribine) in a patient with refractory chronic lymphocytic leukemia. We would like to report another case of tumor lysis syndrome resulting from treatment with 2-chlorodeoxyadenosine. A 59-year-old man presented to the Mayo Clinic for a second opinion concerning therapy for his chronic myelogenous leukemia in chronic phase, which had been diagnosed approximately 18 months earlier. The patient could not tolerate hydroxyurea, had dose-limiting thrombocytopenia when treated with busulfan, and did not want to try interferon.
AB - To the Editor: In the November 18 issue of the Journal, Dann et al.1 reported a case of tumor lysis syndrome after treatment with 2-chlorodeoxyadenosine (cladribine) in a patient with refractory chronic lymphocytic leukemia. We would like to report another case of tumor lysis syndrome resulting from treatment with 2-chlorodeoxyadenosine. A 59-year-old man presented to the Mayo Clinic for a second opinion concerning therapy for his chronic myelogenous leukemia in chronic phase, which had been diagnosed approximately 18 months earlier. The patient could not tolerate hydroxyurea, had dose-limiting thrombocytopenia when treated with busulfan, and did not want to try interferon.
UR - http://www.scopus.com/inward/record.url?scp=0028258625&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028258625&partnerID=8YFLogxK
U2 - 10.1056/NEJM199404143301517
DO - 10.1056/NEJM199404143301517
M3 - Letter
C2 - 8127350
AN - SCOPUS:0028258625
SN - 0028-4793
VL - 330
SP - 1090
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 15
ER -